|US 11,752,096 B2|
|Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors|
|Laman Alani, Menlo Park, CA (US); Kirk William Johnson, Moraga, CA (US); Michael Huang, Redwood City, CA (US); and Chung-Chiang Hsu, Los Altos Hills, CA (US)|
|Assigned to AmMax Bio, Inc., Redwood City, CA (US)|
|Filed by AmMax Bio, Inc., Redwood City, CA (US)|
|Filed on Aug. 22, 2022, as Appl. No. 17/821,459.|
|Application 17/821,459 is a continuation of application No. PCT/US2022/074928, filed on Aug. 12, 2022.|
|Claims priority of provisional application 63/232,611, filed on Aug. 12, 2021.|
|Prior Publication US 2023/0065193 A1, Mar. 2, 2023|
|Int. Cl. A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 19/02 (2006.01); A61K 39/00 (2006.01)|
|CPC A61K 9/0019 (2013.01) [A61P 19/02 (2018.01); A61P 35/00 (2018.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)]||18 Claims|
1. A method for administering an anti-CSF1R (colony stimulating factor 1 receptor) antibody to a mammalian subject, comprising local administration of a composition comprising the antibody at or proximate to a tissue in the mammalian subject, wherein the tissue is a joint impacted with tenosynovial giant cell tumor (TGCT), and wherein the tissue comprises at least a cell that expresses CSF1R on the surface.
11. A method for treating tenosynovial giant cell tumor (TGCT) at a joint in a patient, comprising administering an anti-CSF1R (colony stimulating factor 1 receptor) antibody at or proximate to the TGCT at the joint in the patient.